DP
RVPH

Diadema Partners’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Diadema Partners’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,000
Closed -$140K – 197
2025
Q4 		$140K Buy
+25,000
New +$278K 0.02% 134
2025
Q3 		– Sell
-200,000
Closed -$1.52M – 160
2025
Q2 		$1.52M Buy
+200,000
New +$3.11M 0.46% 51

Other funds holding RVPH

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Diadema Partners's RVPH Position: Q4 2025 in Review

Diadema Partners sold out of REVIVA PHARMA HLDGS INC (RVPH) in Q4 2025, closing a stake of 125,346 shares — an estimated $1.39M sold.

Diadema Partners first reported a position in RVPH in Q1 2025 and held it in 3 quarters. The position peaked at $1.04M in Q2 2025. 48 funds tracked by Wall St. Rank hold RVPH as of Q4 2025.

  • Diadema Partners reported no remaining REVIVA PHARMA HLDGS INC position as of Q4 2025 after selling out during the quarter.
  • Diadema Partners sold 125,346 REVIVA PHARMA HLDGS INC shares in Q4 2025, an estimated $1.39M.
  • Diadema Partners first reported a position in REVIVA PHARMA HLDGS INC in Q1 2025 and held it in 3 quarters.
  • Diadema Partners's REVIVA PHARMA HLDGS INC position peaked at $1.04M in Q2 2025.
  • 48 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q4 2025.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.